Cartesian Therapeutics Inc
NASDAQ:RNAC

Watchlist Manager
Cartesian Therapeutics Inc Logo
Cartesian Therapeutics Inc
NASDAQ:RNAC
Watchlist
Price: 10.76 USD 3.86% Market Closed
Market Cap: 279.2m USD

Intrinsic Value

RNAC's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one RNAC stock under the Base Case scenario is 0.04 USD. Compared to the current market price of 10.76 USD, Cartesian Therapeutics Inc is Overvalued by 100%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

RNAC Intrinsic Value
0.04 USD
Overvaluation 100%
Intrinsic Value
Price
Base Case Scenario
Compare RNAC to

Fundamental Analysis

Company Overview
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about RNAC?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Cartesian Therapeutics Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Cartesian Therapeutics Inc

Current Assets 185.1m
Cash & Short-Term Investments 180.4m
Receivables 1.8m
Other Current Assets 2.9m
Non-Current Assets 224m
Long-Term Investments 2m
PP&E 15.5m
Intangibles 198.8m
Other Non-Current Assets 7.7m
Efficiency

Free Cash Flow Analysis
Cartesian Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Cartesian Therapeutics Inc

Revenue
35m USD
Operating Expenses
-87.4m USD
Operating Income
-52.4m USD
Other Expenses
9.9m USD
Net Income
-42.5m USD
Fundamental Scores

RNAC Profitability Score
Profitability Due Diligence

Cartesian Therapeutics Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Exceptional ROE
Exceptional 1-Year Revenue Growth
Declining ROE
28/100
Profitability
Score

Cartesian Therapeutics Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

RNAC Solvency Score
Solvency Due Diligence

Cartesian Therapeutics Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
53/100
Solvency
Score

Cartesian Therapeutics Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

RNAC Price Targets Summary
Cartesian Therapeutics Inc

Wall Street analysts forecast RNAC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RNAC is 36.89 USD with a low forecast of 16.16 USD and a high forecast of 44.1 USD.

Lowest
Price Target
16.16 USD
50% Upside
Average
Price Target
36.89 USD
243% Upside
Highest
Price Target
44.1 USD
310% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Cartesian Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for RNAC is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

RNAC Insider Trading
Buy and sell transactions by insiders